ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      59,779.36
      0.92%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      10/28/202111:37AMTipRanksAbbVie Stock: Dividend Stalwart on SaleNYSE:ABBVAbbVie Inc
      10/28/20218:15AMPR Newswire (US)AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's DiseaseNYSE:ABBVAbbVie Inc
      10/28/20217:57AMTipRanksAbbVie Q3 Earnings Preview: What’s Ahead?NYSE:ABBVAbbVie Inc
      10/26/20218:30AMPR Newswire (US)Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of PresbyopiaNYSE:ABBVAbbVie Inc
      10/18/20219:25AMTipRanksAbbVie Stock: Unparalleled Dividend Growth-Yield ComboNYSE:ABBVAbbVie Inc
      10/15/20219:19AMDow Jones NewsAbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic ArthritisNYSE:ABBVAbbVie Inc
      10/15/20218:35AMPR Newswire (US)AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)NYSE:ABBVAbbVie Inc
      10/11/20219:47AMTipRanksAbbVie Stock: Price Seems Fair for Biopharmaceutical PlayNYSE:ABBVAbbVie Inc
      10/11/20218:42AMPR Newswire (US)Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer AwarenessNYSE:ABBVAbbVie Inc
      10/07/20211:28PMPR Newswire (Canada)Santé Canada approuve l'emploi de RINVOQ® (upadacitinib), pour le traitement des adultes et des adolescents atteints de dermatite atopique modérée à graveNYSE:ABBVAbbVie Inc
      10/07/20211:22PMPR Newswire (Canada)Health Canada Approves the Use of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic DermatitisNYSE:ABBVAbbVie Inc
      10/07/20219:26AMDow Jones NewsAbbVie Sees Positive Results in Rinvoq StudiesNYSE:ABBVAbbVie Inc
      10/07/20218:16AMPR Newswire (US)AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial SpondyloarthritisNYSE:ABBVAbbVie Inc
      10/07/20218:15AMPR Newswire (US)AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing SpondylitisNYSE:ABBVAbbVie Inc
      10/05/20218:00AMPR Newswire (US)AbbVie to Host Third-Quarter 2021 Earnings Conference CallNYSE:ABBVAbbVie Inc
      10/04/20215:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      10/04/20215:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      10/04/20215:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      10/02/20216:06PMPR Newswire (US)AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021NYSE:ABBVAbbVie Inc
      09/30/20219:45AMPR Newswire (US)AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) CongressNYSE:ABBVAbbVie Inc
      09/30/20218:30AMPR Newswire (US)AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual CongressNYSE:ABBVAbbVie Inc
      09/29/20217:41AMTipRanksAbbVie’s Qulipta Migraine Treatment Bags FDA ApprovalNYSE:ABBVAbbVie Inc
      09/28/20217:30PMDow Jones NewsAbbVie Says FDA Approves Qulipta as Migraine TreatmentNYSE:ABBVAbbVie Inc
      09/28/20216:42PMPR Newswire (US)FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
      09/27/20218:30AMPR Newswire (US)Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey RevealsNYSE:ABBVAbbVie Inc
      09/23/20218:45AMPR Newswire (US)AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) CongressNYSE:ABBVAbbVie Inc
      09/20/20219:10AMPR Newswire (US)AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's DiseaseNYSE:ABBVAbbVie Inc
      09/16/20218:43AMDow Jones NewsAbbVie Submits Regulatory Applications for Treatment of Ulcerative ColitisNYSE:ABBVAbbVie Inc
      09/16/20218:00AMPR Newswire (US)AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
      09/13/20213:24PMTipRanksThis Warren Buffet Stock Could Rise, Following SetbackNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV